Australasian Leukaemia and Lymphoma Group

• NCT05833763

  Phase 2, Recruiting, 42 people, 27 Apr 2023

• Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  Collaborator, Phase 1/2, Recruiting, 112 people, 30 Mar 2023

• NCT05180097

  Collaborator, Phase 2, Recruiting, 84 people, 6 Jan 2022

• NCT04685616

  Collaborator, Phase 3, Recruiting, 1,042 people, 28 Dec 2020

• NCT03140943

  Collaborator, Phase 2, Status unknown, 100 people, 4 May 2017

• NCT00193973

  Collaborator, Phase 2, Completed, 20 people, 19 Sept 2005

• NCT00115700

  Collaborator, Phase 3, Completed, 150 people, 24 Jun 2005

• NCT00053092

  Collaborator, Phase 2, Completed, 82 people, 28 Jan 2003

• NCT00049595

  Collaborator, Phase 3, Completed, 552 people, 27 Jan 2003

• NCT00004179

  Collaborator, Phase 3, Completed, 475 people, 27 Jan 2003

Sources: clinicaltrials.gov